Shares of Opko Health Inc. (NYSE:OPK) traded down 2.9% on Tuesday . The stock traded as low as $9.37 and last traded at $9.52, with a volume of 3,760,140 shares traded. The stock had previously closed at $9.80.

Several analysts recently weighed in on the company. Jefferies Group restated a “hold” rating on shares of Opko Health in a research report on Wednesday, August 17th. Oppenheimer Holdings Inc. restated a “market perform” rating on shares of Opko Health in a research report on Thursday, August 11th. JPMorgan Chase & Co. set a $14.00 price objective on Opko Health and gave the stock a “buy” rating in a research report on Tuesday, August 9th. Zacks Investment Research upgraded Opko Health from a “sell” rating to a “hold” rating in a research report on Tuesday, July 12th. Finally, Standpoint Research upped their price objective on Opko Health from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, June 21st. Five research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $14.05.

The firm’s 50 day moving average is $9.91 and its 200 day moving average is $9.95. The company has a market capitalization of $5.09 billion and a P/E ratio of 38.66.

Opko Health (NYSE:OPK) last announced its quarterly earnings results on Monday, August 8th. The company reported $0.02 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.03) by $0.05. The company earned $357.10 million during the quarter, compared to analysts’ expectations of $324.11 million. During the same quarter last year, the firm posted ($0.09) earnings per share. Opko Health’s revenue for the quarter was up 742.2% compared to the same quarter last year. Equities analysts expect that Opko Health Inc. will post ($0.05) EPS for the current year.

In related news, CEO Phillip Md Et Al Frost purchased 20,000 shares of Opko Health stock in a transaction dated Friday, May 27th. The stock was bought at an average cost of $10.35 per share, for a total transaction of $207,000.00. Following the completion of the transaction, the chief executive officer now owns 3,068,951 shares in the company, valued at $31,763,642.85. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.